Strides Pharma Science (BOM:532531) Cash And Cash Equivalents : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Strides Pharma Science Cash And Cash Equivalents?

Strides Pharma Science's quarterly cash and cash equivalents increased from Jun. 2024 (₹0.00 Mil) to Sep. 2024 (₹1,306.38 Mil) but then stayed the same from Sep. 2024 (₹1,306.38 Mil) to Dec. 2024 (₹0.00 Mil).

Strides Pharma Science's annual cash and cash equivalents increased from Mar. 2022 (₹1,707.30 Mil) to Mar. 2023 (₹3,035.01 Mil) but then declined from Mar. 2023 (₹3,035.01 Mil) to Mar. 2024 (₹1,610.20 Mil).

Strides Pharma Science Cash And Cash Equivalents Historical Data

The historical data trend for Strides Pharma Science's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science Cash And Cash Equivalents Chart

Strides Pharma Science Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

1,822.34

1,258.34

1,707.30

3,035.01

1,610.20

Strides Pharma Science Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															-	1,610.20	-	1,306.38	-

Strides Pharma Science Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Strides Pharma Science (BOM:532531) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Strides Pharma Science Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Strides Pharma Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (BOM:532531) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

STAR:India

Address

Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076

Website

https://www.strides.com

Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines